GE HealthCare and FPT Expand AI-Powered Healthcare Partnership
GE HealthCare and FPT Expand AI-Powered Healthcare Partnership Global IT leader FPT Corporation and GE HealthCare have announced an expanded Strategic Cooperation Agreement aimed at driving innovation in AI-powered healthcare solutions. The new partnership marks a shift from project-based engagement…
Sydnexis Receives Positive CHMP Opinion for SYD-101 in Pediatric Myopia
Sydnexis Receives Positive CHMP Opinion for SYD-101 in Pediatric Myopia Sydnexis, Inc., a pre-commercial biopharmaceutical company, has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for its proprietary…
Saskatchewan Expands Public Coverage for Dexcom CGM Systems
Saskatchewan Expands Public Coverage for Dexcom CGM Systems The Government of Saskatchewan has officially expanded its public coverage for continuous glucose monitoring (CGM) systems, a decision that is set to improve diabetes care for many residents in the province. Effective…
NanoVibronix Announces Distribution Agreement with Dukehill Healthcare in Australia
NanoVibronix Announces Distribution Agreement with Dukehill Healthcare in Australia NanoVibronix, Inc. (NASDAQ: NAOV), a leading medical technology company specializing in non-invasive therapeutic devices, has announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd.…
Tris Pharma to Present Data on Cebranopadol at AAPM PainConnect Meeting
Tris Pharma to Present Data on Cebranopadol at AAPM PainConnect Meeting Tris Pharma, Inc., a biopharmaceutical company focused on commercial-stage development, has announced its participation in the upcoming 2025 American Academy of Pain Medicine (AAPM) PainConnect annual meeting. The conference…
ZAP-X Gyroscopic Radiosurgery Platform Debuts at Kaohsiung Show Chwan Memorial Hospital
ZAP-X Gyroscopic Radiosurgery Platform Debuts at Kaohsiung Show Chwan Memorial Hospital ZAP Surgical Systems, Inc., a leader in non-invasive robotic brain surgery, has announced the installation of Taiwan’s first vault-free ZAP-X® Gyroscopic Radiosurgery® platform at Kaohsiung Show Chwan Memorial Hospital…
Predictmedix AI Closes $100,000 Third Tranche and Launches Smart Health AI Stations
Predictmedix AI Closes $100,000 Third Tranche and Launches Smart Health AI Stations Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP), a leader in AI-powered health screening solutions, is excited to announce the successful completion of the third and final…
RenovoRx Reports Initial Revenues from RenovoCath® and Phase III TIGeR-PaC Trial Update
RenovoRx Reports Initial Revenues from RenovoCath® and Phase III TIGeR-PaC Trial Update RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company focused on developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel FDA-cleared drug delivery device, has announced its financial…
Siemens Healthineers’ Antithrombin Blood Test FDA Cleared as Companion Diagnostic for Sanofi’s Qfitlia Hemophilia Therapy
Siemens Healthineers’ Antithrombin Blood Test FDA Cleared as Companion Diagnostic for Sanofi’s Qfitlia Hemophilia Therapy Siemens Healthineers announced that its Innovance Antithrombin assay has received FDA clearance for a new indication, allowing it to be used as a companion diagnostic…
Epitel’s REMI EEG System Gets Expanded FDA Clearance for Patients Aged One and Up
Epitel’s REMI EEG System Gets Expanded FDA Clearance for Patients Aged One and Up Epitel, a leader in AI-driven brain health solutions, has announced that the U.S. Food and Drug Administration (FDA) has granted expanded 510(k) clearance for the REMI™…
Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint
Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint Corcept Therapeutics Incorporated (NASDAQ: CORT), a company focused on developing treatments for serious endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol, announced that its pivotal…
ENDRA Life Sciences Announces Strategy for Early Detection and Management of Metabolic Diseases with GLP-1 Therapies
ENDRA Life Sciences Announces Strategy for Early Detection and Management of Metabolic Diseases with GLP-1 Therapies ENDRA Life Sciences Inc. (NASDAQ: NDRA), a leader in Thermo-Acoustic Enhanced UltraSound (TAEUS®) technology, recently announced a new strategic direction to develop and deploy…